Start here if you're new
what it is
It sells malpractice, workers' comp, and reinsurance coverage to U.S. customers.
how it gets paid
Last year Proassurance made $1.1B in revenue. Specialty Property and Casualty was the main engine at $0.56B, or 51% of sales.
why growth slowed
Revenue fell 4.6% last year. $828M is the number that matters because it shows the business can still throw off a very large quarter while the sale process is underway.
what just happened
Revenue hit $828M last quarter while EPS came in at $0.34.
At a glance
B balance sheet — gets the job done, barely
5/100 earnings predictability — expect surprises
19.8x trailing p/e — priced about right
3.2% return on capital — nothing to write home about
$1.03 fy2024 eps est
xvary composite: 47/100 — below average
What they do
It sells malpractice, workers' comp, and reinsurance coverage to U.S. customers.
You are buying a niche insurer, not a broad one. It has 1,036 employees and three lines, so one bad claim trend can hit hard. But Specialty P&C kept 84% of customers in 2025, and that is sticky for insurance.
How they make money
$1.1B
annual revenue · their business grew -4.6% last year
Specialty Property and Casualty
$0.56B
3.0%
Workers' Compensation Insurance
$0.31B
5.0%
Segregated Portfolio Cell Reinsurance
$0.14B
+4.0%
Other underwriting and fee income
$0.09B
0.0%
The products that matter
malpractice coverage for healthcare professionals
Medical Professional Liability
core specialty line · 84% retention
This is the core book you are actually backing as a shareholder. An 84% retention rate says customers stay. It does not say claims stay tame.
core line
employer injury insurance
Workers' Compensation
inside the $923M specialty segment
It sits inside the $923M specialty P&C segment, which declined 4.6%. So this is less a growth engine than part of the broader underwriting repair job.
claims exposure
investment income and other operations
Investments & Other
$177M · 16% of revenue
This $177M bucket is the stabilizer. When underwriting gets messy, this is where some of the earnings support comes from. That is useful. It is also a reminder that underwriting has not earned your trust yet.
earnings support
Key numbers
$1.1B
annual revenue
That is the size of the whole business. For an insurer, $1.1B is big enough to matter and small enough to get bought.
3.2%
return on capital
You get 3.2% back for every dollar tied up in the business. That is weak for a stock trading near a takeover price.
$425M
long-term debt
That debt is 25% of capital. If cash gets tight, debt does not care about your narrative.
19.8x
trailing p/e
You are paying 19.8 times trailing earnings for a company that is being bought, not built.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 3 — safer than 50% of stocks
- price stability 40 / 100
- long-term debt $425M (25% of capital)
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for PRA right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Revenue hit $828M last quarter while EPS came in at $0.34.
EDGAR shows quarterly revenue of $828M, up 196% vs. prior year, and EPS of $0.34, up 1,033%. Yahoo Finance consensus says the last earnings print was $0.64 versus $0.15 expected, so the reporting source and consensus source do not line up cleanly.
$828M
revenue
$0.34
eps
67.4%
gross margin
the number that mattered
$828M is the number that matters because it shows the business can still throw off a very large quarter while the sale process is underway.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
PRA is not a broad market story. It is a deal story and an underwriting story. If either one breaks, the valuation math gets less forgiving fast.
high
Merger with The Doctors Company fails or drags
The deal announced in March 2025 is the clearest near-term catalyst on the page. If it slips or breaks, the scale story goes with it and the market is left judging PRA on its stand-alone numbers again.
That would strip away the main strategic reason investors tolerate a premium setup around a 4.6% net margin business.
high
Combined ratio moves back above 100%
Q4's 67.4% combined ratio was excellent, but the page also points to a history that includes combined ratios above 100%. If claims worsen or reserve pressure returns, the core insurance engine goes back to losing money before investments help.
That would turn the nice quarter into a footnote and make the 19.8x trailing p/e look much less comfortable.
med
Low earnings predictability stays low
A 5/100 earnings predictability score is the market's blunt way of saying this business does not produce smooth, dependable quarters. Claims timing, reserve moves, and investment swings can all move the reported result around.
If you pay for stability and do not get it, the upside to $26.00 stops looking very generous.
med
Litigation and governance issues keep stealing attention
The snapshot references shareholder derivative litigation tied to Caremark claims from 2023–2025. That is not the main valuation driver, but it is still a distraction for a company already trying to prove underwriting discipline and close a merger.
You are not buying a clean story. You are buying a business with live operational and legal noise around it.
What would change our mind: if the merger closes and the combined ratio stays under 100% for the next two reported quarters, the turnaround case earns more trust. If the deal breaks or underwriting slips back above 100%, the thesis breaks with it.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
Can the combined ratio stay under 100%
Q4 printed 67.4%. That is excellent. The real test is whether the next few quarters stay profitable on underwriting, not whether one quarter looked unusually clean.
calendar
Q1 2026 earnings report
Estimated report date is May 23, 2026. Consensus is $0.20 in EPS on $260.74M of revenue. You are watching for follow-through, not fireworks.
deal risk
Merger close with The Doctors Company
The agreement was announced in March 2025. Watch for regulatory approval and a firm close. Without it, the main rerating case weakens fast.
trend
Policy retention in the specialty book
Retention is 84% today. If that holds while underwriting improves, the turnaround case gets sturdier. If it slips, you have weaker customer stickiness at the same time you are asking the market for patience.
Analyst rankings
earnings predictability
5 / 100
in human-speak, analysts do not trust this company to produce clean, repeatable quarters.
street price target
$26.00
That is about 7% above the current price. The street is not calling for a breakout. It is calling for limited upside if execution holds.
source: institutional data
Institutional activity
institutional ownership data for PRA is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$24
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive